ArticleLeukemia2024
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07727668 (Feasibility Study of Iberdomide), which is not on this map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility Study of Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.Blood cancer journal · 2026Pooled it
- Efficacy and safety of BCMA-directed CAR T-cell therapy in extramedullary relapsed or refractory multiple myeloma: a meta-analysis.Frontiers in immunology · 2026Pooled it
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.Nature medicine · 2024Pooled it
- Morphologic and immunophenotypic characterization of lymphocytosis following BCMA-targeted CAR-T cell therapy in relapsed/refractory multiple myeloma.Haematologica · 2026Article
- Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.HemaSphere · 2026Article
- Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.CPT: pharmacometrics & systems pharmacology · 2026Article
- CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma.HemaSphere · 2026Article
- Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.Science translational medicine · 2026Article
- Targeting the immunological synapse in multiple myeloma.Discover oncology · 2026Review
- Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.Leukemia · 2026Review
- MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel.Leukemia · 2026Article
- Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells.Nature biomedical engineering · 2026Article
- Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.HemaSphere · 2026Article
- Process Systems Engineering in Precision Medicine: Opportunities in Autologous CAR-T Therapy.Engineering in life sciences · 2026Review
- Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.Blood cancer journal · 2026Article
- Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Targeted oncology · 2026Review
- International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.Blood advances · 2025Article
- Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patients.HemaSphere · 2025Article
- Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Following BCMA CAR T FailureTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Molecular and immunological determinants of long-term survival in multiple myeloma.Blood advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells. Additionally, we addressed side effects, like cytokine release syndrome (CRS) and cytopenia. Our results show that in vivo expansion of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.